Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded at The Goldman Sachs Group

Corvus Pharmaceuticals (NASDAQ:CRVS) was upgraded by investment analysts at The Goldman Sachs Group to a “strong-buy” rating in a research note issued on Friday, MarketBeat reports.

Several other analysts have also commented on the company. HC Wainwright raised their price objective on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Mizuho set a $30.00 price objective on Corvus Pharmaceuticals in a report on Thursday, January 29th. Oppenheimer reissued an “outperform” rating and issued a $33.00 price objective (up from $32.00) on shares of Corvus Pharmaceuticals in a report on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Wall Street Zen lowered shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.33.

Corvus Pharmaceuticals Stock Up 11.3%

Shares of Corvus Pharmaceuticals stock opened at $16.74 on Friday. The firm has a market cap of $1.41 billion, a PE ratio of -33.48 and a beta of 0.97. The business has a 50-day moving average price of $16.14 and a 200 day moving average price of $12.03. Corvus Pharmaceuticals has a twelve month low of $3.15 and a twelve month high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, sell-side analysts expect that Corvus Pharmaceuticals will post -0.63 EPS for the current year.

Institutional Trading of Corvus Pharmaceuticals

Several large investors have recently bought and sold shares of the business. SG Americas Securities LLC grew its stake in Corvus Pharmaceuticals by 76.9% during the 1st quarter. SG Americas Securities LLC now owns 35,420 shares of the company’s stock valued at $518,000 after acquiring an additional 15,399 shares in the last quarter. Invesco Ltd. grew its stake in Corvus Pharmaceuticals by 12.7% during the 4th quarter. Invesco Ltd. now owns 43,583 shares of the company’s stock valued at $336,000 after acquiring an additional 4,910 shares in the last quarter. Virtus Investment Advisers LLC grew its stake in Corvus Pharmaceuticals by 18.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 31,783 shares of the company’s stock valued at $245,000 after acquiring an additional 4,946 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Corvus Pharmaceuticals by 74.7% in the 4th quarter. Wellington Management Group LLP now owns 314,683 shares of the company’s stock valued at $2,423,000 after buying an additional 134,508 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of Corvus Pharmaceuticals in the 4th quarter valued at approximately $5,304,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.